BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J Clin Invest 2021;131:144486. [PMID: 33571163 DOI: 10.1172/JCI144486] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Carroll D. RNA in Therapeutics: CRISPR in the Clinic. Mol Cells 2023;46:4-9. [PMID: 36482771 DOI: 10.14348/molcells.2022.0163] [Reference Citation Analysis]
2 Rothemejer FH, Lauritsen NP, Juhl AK, Schleimann MH, König S, Søgaard OS, Bak RO, Tolstrup M. Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus. Viruses 2023;15. [PMID: 36680242 DOI: 10.3390/v15010202] [Reference Citation Analysis]
3 Davey BC, Pampusch MS, Cartwright EK, Abdelaal HM, Rakasz EG, Rendahl A, Berger EA, Skinner PJ. Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells. Front Immunol 2022;13:1032537. [PMID: 36582226 DOI: 10.3389/fimmu.2022.1032537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gibbs KD, Schott BH, Ko DC. The Awesome Power of Human Genetics of Infectious Disease. Annu Rev Genet 2022;56:41-62. [PMID: 35697043 DOI: 10.1146/annurev-genet-080320-010449] [Reference Citation Analysis]
5 Muvarak N, Li H, Lahusen T, Galvin JA, Kumar PN, Pauza CD, Bordon J. Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1044713] [Reference Citation Analysis]
6 Chen M, Li M, Budai MM, Rice AP, Kimata JT, Mohan M, Wang J. Clearance of HIV-1 or SIV reservoirs by promotion of apoptosis and inhibition of autophagy: Targeting intracellular molecules in cure-directed strategies. J Leukoc Biol 2022;112:1245-59. [PMID: 35362118 DOI: 10.1002/JLB.4MR0222-606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fesnak AD, Siegel DL. Chimeric antigen receptor T cells and other cellular immunotherapies. Rossi's Principles of Transfusion Medicine 2022. [DOI: 10.1002/9781119719809.ch55] [Reference Citation Analysis]
8 Lu Y, Happi Mbakam C, Song B, Bendavid E, Tremblay J. Improvements of nuclease and nickase gene modification techniques for the treatment of genetic diseases. Front Genome Ed 2022;4. [DOI: 10.3389/fgeed.2022.892769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Freen-van Heeren JJ. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV. BioTech 2022;11:25. [DOI: 10.3390/biotech11030025] [Reference Citation Analysis]
10 Kim TH, Lee SW. Therapeutic Application of Genome Editing Technologies in Viral Diseases. Int J Mol Sci 2022;23:5399. [PMID: 35628210 DOI: 10.3390/ijms23105399] [Reference Citation Analysis]
11 Chen X, Jia L, Zhang X, Zhang T, Zhang Y. One arrow for two targets: potential co-treatment regimens for lymphoma and HIV. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Karuppusamy KV, Demosthenes JP, Venkatesan V, Christopher AC, Babu P, Azhagiri MK, Jacob A, Ramalingam VV, Rangaraj S, Murugesan MK, Marepally SK, Varghese GM, Srivastava A, Kannangai R, Thangavel S. The CCR5 Gene Edited CD34+CD90+ Hematopoietic Stem Cell Population Serves as an Optimal Graft Source for HIV Gene Therapy. Front Immunol 2022;13:792684. [DOI: 10.3389/fimmu.2022.792684] [Reference Citation Analysis]
13 Li S, Holguin L, Burnett JC. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Mol Ther Methods Clin Dev 2022;24:321-31. [PMID: 35229006 DOI: 10.1016/j.omtm.2022.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Claireaux M, Robinot R, Kervevan J, Patgaonkar M, Staropoli I, Brelot A, Nouël A, Gellenoncourt S, Tang X, Héry M, Volant S, Perthame E, Avettand-Fenoël V, Buchrieser J, Cokelaer T, Bouchier C, Ma L, Boufassa F, Hendou S, Libri V, Hasan M, Zucman D, de Truchis P, Schwartz O, Lambotte O, Chakrabarti LA. Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry. Nat Commun 2022;13:521. [PMID: 35082297 DOI: 10.1038/s41467-022-28130-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR, Wigdahl B. Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Front Immunol 2022;12:816515. [DOI: 10.3389/fimmu.2021.816515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Knipping F, Newby GA, Eide CR, McElroy AN, Nielsen SC, Smith K, Fang Y, Cornu TI, Costa C, Gutierrez-Guerrero A, Bingea SP, Feser CJ, Steinbeck B, Hippen KL, Blazar BR, McCaffrey A, Mussolino C, Verhoeyen E, Tolar J, Liu DR, Osborn MJ. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing. Mol Ther 2022;30:130-44. [PMID: 34737067 DOI: 10.1016/j.ymthe.2021.10.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
17 Lau CY, Adan MA, Maldarelli F. Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection. Viruses 2021;13:2512. [PMID: 34960781 DOI: 10.3390/v13122512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Patro SC, Niyongabo A, Maldarelli F, Kearney MF. New Approaches to Multi-Parametric HIV-1 Genetics Using Multiple Displacement Amplification: Determining the What, How, and Where of the HIV-1 Reservoir. Viruses 2021;13:2475. [PMID: 34960744 DOI: 10.3390/v13122475] [Reference Citation Analysis]
19 Maynard LH, Humbert O, Peterson CW, Kiem HP. Genome editing in large animal models. Mol Ther 2021;29:3140-52. [PMID: 34601132 DOI: 10.1016/j.ymthe.2021.09.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Terrade G, Huot N, Petitdemange C, Lazzerini M, Orta Resendiz A, Jacquelin B, Müller-Trutwin M. Interests of the Non-Human Primate Models for HIV Cure Research. Vaccines (Basel) 2021;9:958. [PMID: 34579195 DOI: 10.3390/vaccines9090958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li S, Holguin L, Burnett JC. CRISPR/Cas9-mediated gene disruption of endogenous co-receptors confers broad resistance to HIV-1 in human primary cells and humanized mice.. [DOI: 10.1101/2021.06.30.450601] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Campillo-Davo D, De Laere M, Roex G, Versteven M, Flumens D, Berneman ZN, Van Tendeloo VFI, Anguille S, Lion E. The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. Pharmaceutics 2021;13:396. [PMID: 33809779 DOI: 10.3390/pharmaceutics13030396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
23 Chang XL, Wu HL, Webb GM, Tiwary M, Hughes C, Reed JS, Hwang J, Waytashek C, Boyle C, Pessoa C, Sylwester AW, Morrow D, Belica K, Fischer M, Kelly S, Pourhassan N, Bochart RM, Smedley J, Recknor CP, Hansen SG, Sacha JB. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol 2021;12:794638. [PMID: 34868084 DOI: 10.3389/fimmu.2021.794638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]